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Abstract
Background: Epidermal growth factor receptor (EGFR) overexpression is observed in signiﬁ  cant proportions of non-small 
cell lung carcinomas (NSCLC). Furthermore, overactivation of vascular endothelial growth factor (VEGF) leads to increased 
angiogenesis implicated as an important factor in vascularization of those tumors. 
Patients and Methods: Using tissue microarray technology, forty-parafﬁ  n (n = 40) embedded, histologically conﬁ  rmed   
primary NSCLCs were cored and re-embedded into a recipient block. Immunohistochemistry was performed for the deter-
mination of EGFR and VEGF protein levels which were evaluated by the performance of computerized image analysis. 
EGFR gene ampliﬁ  cation was studied by chromogenic in situ hybridization based on the use of EGFR gene and chromo-
some 7 centromeric probes.
Results: EGFR overexpression was observed in 23/40 (57.5%) cases and was correlated to the stage of the tumors (p = 0.001), 
whereas VEGF was overexpressed in 35/40 (87.5%) cases and was correlated to the stage of the tumors (p = 0.005) and to 
the smoking history of the patients (p = 0.016). Statistical signiﬁ  cance was assessed comparing the protein levels of EGFR 
and VEGF (p = 0.043, k = 0.846). EGFR gene ampliﬁ  cation was identiﬁ  ed in 2/40 (5%) cases demonstrating no association 
to its overall protein levels (p = 0.241), whereas chromosome 7 aneuploidy was detected in 7/40 (17.5%) cases correlating 
to smoking history of the patients (p = 0.013).
Conclusions: A signiﬁ  cant subset of NSCLC is characterized by EGFR and VEGF simultaneous overexpression and 
maybe this is the eligible target group for the application of combined anti-EGFR/VEGF targeted therapies at the basis of 
genetic deregulation (especially gene ampliﬁ  cation for EGFR).
Keywords: Non-small cell lung carcinoma, tissue microarrays, genes, epidermal growth factor receptor, vascular endothe-
lial growth factor.
Introduction
Although the design and development of novel therapeutic strategies demonstrate encouraging results 
in patients who suffer from non-small cell lung carcinoma (NSCLC), there is an increased need for a 
more rational selection of those patients who could earn survival beneﬁ  ts by the combination of conven-
tional, systemic chemotherapy and targeted therapy, such as monoclonal antibodies or intracellular 
tyrosine-kinase inhibitors (Baselga and Arteaga, 2006). Disruption of crucial signal transduction 
pathways, which under molecular deregulation lead to upregulated proliferation, metastasis, and 
angiogenesis, is a challenge for combined targeted therapeutic strategies (Liebmann, 2001). 
Epidermal growth factor receptor (EGFR) gene is located on chromosome 7 (7p12) and its product 
is a 170 kDa protein, comprising of three major functional domains: an extracellular ligand-binding 
domain, a hydrophobic transmembrane domain and a cytoplasmic tyrosine-kinase domain (Harari, 276
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2004). Ligands, such as EGF or TGF-α, bind to 
the extracellular domain of the receptor and trigger 
a cataract of reactions, including dimerization and 
phosphorylation of the intracellular domain and 
ﬁ  nally signal transduction to nucleus is mediated 
by the involvement of RAS/RAF/MAPK proteins 
predominantly and via an alternative pathway 
(PI3/AKT/mTOR) (Molina and Adjei, 2006). In 
aggressive tumors, such as glioblastomas, some 
studies have shown that EGFR gene ampliﬁ  cation 
is correlated to shorter survival time and resistance 
to radiotherapy (Marquez et al. 2004). Almost 
recently, novel targeted therapeutic strategies 
including anti-EGFR agents, such as monoclonal 
antibodies (cetuximab) and small molecules 
(geﬁ  tinib, erlotinib) have been approved for the 
treatment in some types of EGFR-dependent 
cancers, such as colon or lung and pancreatic 
(Barder et al. 2004; Jensen et al. 2006; Krempien 
et al. 2005). Although EGFR protein overexpres-
sion is observed in signiﬁ  cant proportions (~40 to 
80%) of NSCLCs, the crucial process for a succes-
sive targeted therapeutic approach (survival 
beneﬁ  ts) remains the identiﬁ  cation of speciﬁ  c gene 
deregulation mechanisms (Ji et al. 2006; Kosaka 
et al. 2004). Some studies have already shown the 
association between speciﬁ  c mutations of EGFR 
tyrosine-kinase intracellular chains and the 
response to small molecules acting as inhibitors in 
this domain, such as geﬁ  tinib or erlotinib (Muko-
hara et al. 2005; Perez-Soler et al. 2004; Kris et al. 
2003). In contrast, there are controversial results 
regarding to the efﬁ  cacy of monoclonal antibodies 
therapy in those patients (Raben et al. 2005; 
Thienelt et al. 2005). Furthermore, EGFR gene 
ampliﬁ  cation seems to be a relatively rare (∼5% 
to15%) but signiﬁ  cant molecular deregulation 
mechanism affecting the response to those agents 
(Hirch et al. 2003).
Vascular epithelial growth factor (VEGF), also, 
has been characterized as the key mediator of 
angiogenesis in cancers of different types (Ellis 
et al. 2006). VEGF gene is a member of the PDGF/
VEGF growth factor family and is located on 
chromosome 6 (6p12). Its protein product 
(isomorph A) is a glycosylated mitogen acting as 
an endothelial cell growth factor, promoter of cell 
migration, and inhibitor of apoptosis (Voelkel et al. 
2006). Although this cytokine normally induces 
endothelial proliferation and increases vascular 
permeability, it is also involved in tumor-associated 
angiogenesis by its overexpression (Zhu et al. 
2006). Under hypoxic conditions, HIF 1α-α tran-
scription factor responsible for the regulation of 
oxygen homeostasis—is activated through PI3 
kinase – AKT and MAPK–ERK pathways, binding 
with its complementary factor HIF 1β to the 
promoters of genes that mediate glycolysis and 
angiogenesis, such as VEGF (Chang et al. 2006; 
Strieter, 2005). Aberrant secretion of VEGF due to 
hypoxia, activation of oncogenes, and even EGFR 
or an abnormal hormonal activity leads to an 
uncontrolled binding to speciﬁ  c receptors such as 
VEGFR-1or VEGFR-2 (Langer and Natale, 2005; 
Matsumori et al. 2006). This process triggers a 
cataract of reactions including phosphorylation of 
intracellular tyrosine-kinase chains and ﬁ  nally 
leads to tumor angiogenesis characterized by an 
abnormal structurally and functionally vasculature 
(Thorpe, 2004; Siemann and Shi, 2004). Concerning 
NSCLC, some recently published Phase II–III 
studies have shown encouraging results due to 
combination of anti-VEGF monoclonal antibodies 
(bevacizumab) and chemotherapeutic agents, such 
as carboplatin, paclitaxel or anti-EGFR inhibitors, 
such as cetuximab or geﬁ  tinib (Morelli et al. 2006; 
Robert et al. 2005; Hebst et al. 2005). Despite this 
progress in the management of those patients, 
identiﬁ  cation of speciﬁ  c molecular criteria is a 
challenge for increased response rates (Pao et al. 
2004). 
Using tissue microarrays (TMAs) and comput-
erized image analysis (CIA) we evaluated EGFR 
and VEGF protein expression by Immunohisto-
chemistry (IHC) and also we analyzed EGFR gene 
status by Chromogenic in situ Hybridization 
(CISH) in order to identify potential signiﬁ  cant 
correlation of these two genes in NSCLCs.
Materials and Methods
We obtained, for the purposes of our study, forty 
(n = 40) formalin ﬁ  xed and parafﬁ  n embedded 
archival tissue samples of histologically proven 
NSCLC including 27 adenocarcinomas (AC), 
2 bronchioloalveolar carcinomas (BAC), 9 squa-
mous cell carcinomas (SCC) and 2 large cell 
carcinomas (LCC). Most of them were initially 
diagnosed by the performance of CT guided ﬁ  ne 
needle aspiration (FNA), using ThinPrep method 
(Cytyc, U.S.A.). According to our therapeutic 
protocols, the patients classiﬁ  ed as stage I and II 
received only surgical therapy (radical ablation: 
lobectomies and pneumonectomies, associated 277
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with radical lynphadenectomy). Patients in stage 
IIIa or IIIb had been projected to follow new adju-
vant chemotherapy (cis-platin, vinorelbine, 
gemcitabine or combined treatment between them), 
radiotherapy (2000–6500 cGy) and in case of 
shrink of the initial mass, 2–3 weeks after the 
therapy were submitted for surgical ablation of the 
tumor. Surgical specimens were obtained by the 
performance of open minimal surgery biopsies 
(VATS), in some cases of stage III and the only 
one IV case included in this study. All corre-
sponding Hematoxylin and Eosin (H&E)-stained 
slides were reviewed by two pathologists for 
confirmation of diagnosis and classification 
according to World Health Organization (WHO) 
grading and staging (TNM system) criteria for lung 
cancer. The tissue samples were referred to 31 male 
(mean age: 57) and 9 female (mean age: 62) 
patients. Clinicopathological data are demonstrated 
in Table 1.
TMA construction
Areas of interest were identiﬁ  ed in H&E stained 
slides by a conventional microscope (Olympus 
BX-50, Melville, NY, U.S.A.). Selection of those 
areas was performed on the basis of tumor sufﬁ  -
ciency and accurate histological conﬁ  rmation, 
avoiding sites of necrosis or bleeding. The corre-
sponding parafﬁ  n blocks were obtained for the 
construction of one TMA block. Using ATA-100 
apparatus (Chemicon International, Temecula, CA, 
U.S.A.), all of the source blocks were cored two 
times (in order to secure the presence of each case 
in the ﬁ  nal block) and 1-mm diameter tissue cylin-
drical cores were transferred from each conven-
tional donor block to the recipient block. The ﬁ  nal 
constructed TMA block contained 85 cores of 
tissue cylindrical specimens, including ﬁ  ve cores 
of the control group (normal appearing lung 
epithelia). After 3 mm microtome sectioning and 
H&E staining, we observed microscopically that 
all examined cases were represented by at least one 
(7 cases) or two tissue spot (33 cases)-conﬁ  rmation 
of the adequacy of cylindrical specimens. 
Antibodies and probes 
Ready-to-use EGFR monoclonal mouse antibody 
(clone 31G7-Zymed/InVitrogen, San Fransisco, 
U.S.A.) recognizing predominantly the extracel-
lular domain of EGFR protein and not reacting 
with other erbB receptors used. Similarly, anti-
VEGF polyclonal antibody (LYL-Biogenex, San 
Ramon, CA, U.S.A.) recognizing the Aisoform 
applied. EGFR gene status was determined using 
Table 1. Clinicopathological data (NSCLC cases). 
   n = 40  %
Gender Male  31  78
 Female  9  22
Histology AC  27  68
 SCC  9  22
 BAC/LCC  2/2  10
Grade 1 6  15
 2  18  45
 3  16  40
Stage I 7  18
 II  16  40
 III/IV  17  42
Smoking status  Non  16  40
 Active  18  45
 Former  6  15
Ac, adenocarcinoma; SCC, squamous cell carcinoma; BAC, bronchioalveolar adenocarci-
noma; LCC, large cell carcinoma. The Department of Pathology (417 VA Hospital-NIMTS, 
Athens, Greece) the local ethical committee gave permission to use those tissues for 
research purposes. Oral informed consent was obtained from each patient and the study 
protocol conforms to the ethical guidelines of the “World Medical Association Declaration of 
Helsinki—Ethical Principles for Medical Research Involving Human Subjects” adopted by the 
18th WMA General Assembly, Helsinki, Finland, June 1964, as revised in Tokyo 2004.278
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the ready to use SPOT LIGHT EGFR DNA Probe 
(Zymed/InVitrogen, San Fransisco, U.S.A.). This 
digoxygenin-labeled probe is located on 7p12 and 
covers the entire EGFR gene area. A chromosome 
7 status was determined by the ready to use biotin-
labeled chromosome 7 centromeric probe (Zymed/
InVitrogen, San Fransisco, U.S.A.) recognizing the 
speciﬁ  c repetitive centromeric DNA sequences 
known as α-satellite DNA.
Immunohistochemistry (IHC)
As described above in the parafﬁ  n sections of TMA 
block, the IHC for EGFR and VEGF antigens was 
carried out on 3 μm serial. Two slides were depa-
rafﬁ  nized and rehydrated. The ﬁ  rst of them was 
enzyme digested (proteinase K) for 10 min at 37 ºC. 
The NBA kit (Zymed/InVitrogen, San Fransisco, 
U.S.A) was used for the following detection steps. 
Blocking solution was applied to the slides for 10 
min, followed by incubation for 1 h using the 
EGFR monoclonal antibody (dilution 1:10) at room 
temperature. Following incubation with the 
secondary antibody for 10 min, diaminobenzidine-
tetrahydrocloride-DAB (0.03%) containing 0.1% 
hydrogen peroxide was applied as a chromogen 
and incubated for 5 min. Sections were counter-
stained, dehydrated and cover-slipped. For VEGF 
expression, the second slide was incubated for 1 h 
using the VEGF polyclonal antibody (dilution 
1:60) without enzyme digestion. For negative 
control slides, the primary antibodies were omitted. 
Both IHC protocols were performed by the use of 
an automated staining system (I 6000 – Biogenex, 
San Ramon, CA, U.S.A.). Membranous and sub-
membranous cytoplasmic staining was considered 
acceptable for those two markers, respectively, 
according to manufacturer’s data sheet. (Fig. 1a). 
Colon cancer tissue sections overexpressing EGFR 
and VEGF, and normal appearing colon and lung 
epithelia were used as a positive and negative 
control, respectively. EGFR protein expression 
levels were evaluated semi-quantitatively by using 
Zymed’s Evaluation Guidelines. According to the 
scoring guidelines, the examined cases were clas-
siﬁ  ed as follows: Score 0: no staining or membrane 
staining in <10% of tumor cells; Score 1+: faint 
membrane staining in >10% of tumor cells; Score 
2+: weak or moderate complete membrane staining 
in >10% of tumor cells and Score 3+: strong, 
complete membrane staining in >10% of tumor 
cells. Scores of 0 and 1+ were considered as 
negative for EGFR expression while Scores 
2 + and 3 + as positive (overexpression). VEGF 
protein levels were evaluated semi-quantitatively 
also using the modification described above 
predominantly for cytoplasmic/membranous focal 
or diffuse staining pattern.
Chromogenic in situ hybridization 
(CISH)
CISH SPOT-Light Chromogenic ISH Detection 
Kit was applied. CISH for chromosome 7 status 
and EGFR gene analysis was performed on 5 μm 
thick parafﬁ  n serial sections of the TMA block 
described above. Two slides were incubated 
at 37 
oC overnight followed by 2 h incubation at 
60 
oC and then deparafﬁ  nized in xylene two  times, 
5 min each and in ethanol three times, 3 min each. 
The slides were rinsed in deionised water and then 
placed in a coplin jar containing CISH FFPE Pre-
treatment Buffer (CISH Tissue Pre-treatment Kit, 
Zymed). For heat pre-treatment, the coplin jar was 
capped, loosely screwed, placed in a pressure 
cooker and timed for 10 min after the pressure built 
up. The slides, then, were immediately washed in 
deionised water followed by enzyme digestion, 
which was performed by covering the sections with 
pepsin (CISH Tissue Pre-treatment Kit, Zymed) 
for 5 min at 37 
oC. The slides were washed with 
deionised water, dehydrated with graded ethanol 
and air-dried. Ready to use dig-labeled EGFR gene 
Figure 1. EGFR overexpression was found in a case of NSCLC. (A) 
A tissue microarray core (diameter 1 mm) demonstrating EGFR high 
value of protein expression (conventional score 3+). Original mag-
niﬁ  cation: 10× (B). Note in the same case the speciﬁ  c—for protein 
overexpression - complete, ‘‘ring like’’, dense membranous pre-
dominantly immunostaining pattern (clone 31G7). Original magniﬁ  ca-
tion: 40× upper inside. Chromosome 7 aneuploidy by CISH analysis. 
Note 3 and 4 centromeric signals per nucleus (black arrows) down 
inside. EGFR gene ampliﬁ  cation by CISH analysis. Note 6–10 gene 
copies as dark blue scattered signals or small clusters of them (red 
arrows) per nucleus. Original magniﬁ  cation for CISH: 40×.279
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and biotin-labeled chromosome 7 centromere 
probe was applied to each section, respectively. 
Twenty microliter of probe was applied to each of 
the TMA sections. The tissue sections containing 
the added probe were denatured by placing the 
slides in a polymerase chain reaction (PCR) 
machine equipped with a slide block at 94 °C for 
5 min. The slides were then placed in a moist slide 
box and incubated at 37 °C for overnight hybrid-
ization. The sections were stringently washed in 
0.5x standard saline citrate at 75 °C for 5 min. The 
CISH Polymer and the Horseradish (HRP) Detec-
tion Kit (Zymed/InVitrogen, San Fransisco, 
U.S.A.)—containing similar steps to IHC—were 
used. Shortly, afterwards TMA sections were 
placed in 3% H2O2 and diluted with methanol for 
10 min to block endogenous peroxidase. To block 
unspeciﬁ  c staining, Cas Block
TM (Zymed/InVit-
rogen, San Fransisco, U.S.A.) was applied and 
incubated for 10 min. Following incubation with 
mouse anti-dig for 30 min and then polymerised 
HRP conjugated anti-mouse for 30 min, the EGFR 
probe was visualized by DAB development (CISH 
Polymer Detection Kit, Zymed). The biotin labeled 
Chr 7 centromere probe was detected by incubation 
with HRP conjugated streptavidin for 30 min, 
followed by DAB development (CISH Centromere 
Detection Kit, Zymed) for 30 min. TMA sections 
were lightly counterstained with hematoxylin and 
dehydrated in graded ethanol. At the end of the 
process, CISH centromere signals or gene copies 
were easily visualized as dark brown/blue scattered 
or in small clusters dots, using a conventional, 
bright-ﬁ  eld microscope (Fig. 1b). 
Interpretation of EGFR gene and chromosome 7 
centromere signal results was based on Zymed’s 
Evaluation Chart for CISH. According to this guide, 
two gene copies per nucleus demonstrate normal 
EGFR gene pattern, whereas 6–10 or small clusters 
characterize a low-level gene ampliﬁ  cation. In this 
case, chromosome 7 status must be evaluated to 
exclude aneuploidy (3–5 centromeric signals per 
nucleus; diploid pattern demonstrates normal chro-
mosome status). Finally, high gene ampliﬁ  cation 
level is characterized by the presence of more than 
10 gene copies or large clusters of them per nucleus 
in more than 50% of the examined cells. 
Computerized image analysis (CIA)
In order to evaluate the IHC results-speciﬁ  cally 2+ 
and 3+, we semi-quantitatively characterized 
cases-in an accurate and faster way. Then, 
we perform CIA by using a semi-automated 
system with the following hardware features: Intel 
Pentium IV, MATROX II Card Frame Grabber, 
Digital Camera Microwave systems (800 × 600), 
Μicroscope Olympus BX–50 and the following 
software: Windows XP/Image Pro Plus, version 
3.0-Media Cybernetics 1997. Measurements of 
EGFR and VEGF staining intensity values were 
performed in ﬁ  ve optical ﬁ  elds per case and at a 
magniﬁ  cation of 400 × (Fig. 2). Using normal 
epithelia as control group and basis for the evalu-
ation of protein expression levels, we compared 
them to the examined tumors.  We observed that 
EGFR and  VEGF expression levels—character-
ized as Low, Moderate and High-ranged between 
discrete values. Interpretation of staining intensity 
values (range 0–255) is demonstrated in Table 2.
Statistical analysis
Associations between variables including protein 
expression levels, gene, and chromosome status 
and clinicopathological parameters such as gender, 
tumor histology, smoking history, grade and stage 
were performed by the application of χ test esti-
mated along with its 95% CI (SPSS Inc., Chicago 
IL v.11.0). Two tailed p values < 0.05 were consid-
ered statistically signiﬁ  cant. Cohen’s inter-rater 
kappa was also estimated along with its 95% CI to 
evaluate concordances between the two examined 
proteins. By its deﬁ  nition, a κ value of 1 denotes 
complete agreement, values of more than 0.75 are 
characterized as excellent agreement, values 
between 0.40 and 0.75 show fair to good agree-
ment, values more than 0 but less than 0.40 show 
poor agreement, and a kappa value of 0 indicates 
that the observed agreement is equal to chance. 
Figure 2. VEGF protein expression evaluated by Computerized 
Image analysis shows Reddish areas that represent cytoplasmic and 
membranous immunostaining.280
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Total (IHC and CISH) results are described in 
Table 2.
Results and Analysis
EGFR and VEGF IHC assessment
IHC results were successfully obtained from all 
the forty NSCLC cases. EGFR overexpression was 
observed in 23/40 (57.5%) cases. Concerning 
histological type, protein overexpression was 
observed in 12/27 ACs, 8/9 SCCs, 1/2 BACs and 
2/2 LCCs. According to the conventional evalua-
tion criteria, 8 cases were evaluated as 2+ and 15 
cases as 3+. Computerized image analysis for 
EGFR protein staining intensity levels showed that 
6 cases demonstrated moderate values, whereas 17 
cases high values. EGFR protein expression was 
statistically associated with stage (p = 0.001), but 
not with grade (p = 0.325), and histological type 
of the examined tumors (p = 0.133). Speciﬁ  cally, 
biphasic EGFR immunostaining pattern (membra-
nous and cytoplasmic) was observed in 12/23 
(52.1%) cases and interestingly was found to be 
correlated to advance stage (p = 0.001), and also 
to grade (p = 0.046). Additionally, 1/5 cases of the 
normal appearing epithelia demonstrated moderate 
value of EGFR protein overexpression (2+). EGFR 
protein levels were not associated to gene status 
(p = 0.241), chromosome status (p = 0.489), and 
smoking history (p = 0.733), respectively.
VEGF overexpression was observed in 35/40 
(87.5%) cases. Concerning histological type, 
protein overexpression was observed in 23/27 ACs, 
9/9 SCCs, 2/2 BACs and 1/2 LCCs. According to 
the conventional evaluation criteria, 17 cases were 
evaluated as 2+ and 18 cases as 3+. Computerized 
image analysis for VEGF protein staining intensity 
levels showed that 20 cases demonstrated moderate 
values, whereas 15 cases high values. VEGF 
protein expression was statistically associated with 
stage (p = 0.005) and smoking status (p = 0.016), 
but not with grade (p = 0.229), and histological 
type of the examined tumors (p = 0.211). All those 
protein overexpression cases demonstrated a 
biphasic immunostain pattern (membranous and 
diffuse cytoplasmic). Additionally, 2/5 cases of the 
normal appearing epithelia demonstrated moderate 
value of VEGF protein overexpression (2+). Inter-
estingly, by correlating EGFR to VEGF protein 
levels, we observed a statistical significance 
(p = 0.043), and a high interrater kappa value 
(k = 0.846). Combined EGFR and VEGF overex-
pression (overall High and Moderate values) was 
observed in 22/40 (55%) cases and a statistical 
signiﬁ  cance was established correlating to stage 
of those tumors (p = 0.001).
EGFR gene and chromosome 7 
CISH assessment
CISH results were also successfully obtained from 
all the examined cases. In cases with EGFR gene 
ampliﬁ  cation, 6–10 scattered copies were detected 
in cell sub-populations (low ampliﬁ  cation status). 
This genetic event was observed in 2/40 cases (5%) 
linked to histological type (both of them were AC 
cases) and to normal (diploid) chromosome status. 
In EGFR gene, numerical alterations (ampliﬁ  ca-
tion) were not associated with the parameters 
already referred (grade: p = 0.276, stage: p = 0.330, 
smoking history (p = 0.076) and histological type: 
Table 2. Combined IHC and CISH results.
n = 40  EGFR gene status  p value  Chr 7 status    p value
  Normal Ampliﬁ  cation   Normal  Aneuploidy
EGFR IHC     0.241      0.489
2+/3+ (M/H values)  21  2    18  5
0/1+   17  0    15  2
    
VEGF IHC     0.349      0.917
2+/3+ (M/H values)  33  2    29  6
0/1+ 5  0    4  1
M/H values: Staining intensity values represent gray scale levels between 0 (black) and 255 (white). In this study, Low/Negative values 
ranged between 132–255, (0/1+), Moderate (M) values ranged between 118 and 131, whereas High (H) values ranged between 67–112
P values: chi square test (Cl 99%)
EGFR IHC vs VEGF IHC: Kappa (Cl 95%) = 0.846281
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p = 0.798). Chromosome 7 instability (aneuploidy, 
observed as 3–5 dots per nucleus) was detected in 
7/40 (17.5%) cases. All other cases were diploid 
with regard to chromosome 7 status (2 signals per 
nucleus). Signiﬁ  cant statistical correlation was not 
observed by correlating chromosomal status to 
those parameters as they are mentioned before 
(p = 0.757, p = 0.297, and p = 0.540, respectively) 
and also to EGFR gene status (p = 0.504). Interest-
ingly, by correlating chromosome 7 pattern to 
smoking history of the patients, we observed a 
strong statistical signiﬁ  cance (p = 0.013).  Finally, 
we did not detect gene or chromosome numerical 
alterations in the control group (normal epithelia). 
Discussion
Our study was designed to investigate the association 
between EGFR and VEGF alterations in NSCLCs 
based on a TMAs substrate. Although a signiﬁ  cant 
proportion of the examined tumors demonstrated 
EGFR protein overexpression, the speciﬁ  c mechanism 
of gene ampliﬁ  cation was identiﬁ  ed only in a small 
percentage (5%). The highest rate of EGFR strong 
positivity (3+/High staining intensity values) was 
observed in SCCs (88.8%). In contrast, gene ampliﬁ  -
cation was detected by CISH in two cases of ACs 
overexpressing EGFR. Other studies using PCR, 
FISH or CISH method have shown different propor-
tions of EGFR gene ampliﬁ  cation  and there are 
controversial results correlating protein expression 
and gene status (Cappuzo et al. 2006; Awaya et al. 2005; 
Reinmuth et al. 2000). It seems that the majority of 
EGFR overexpressed NSCLCs, especially SCCs are 
associated to different molecular deregulation mech-
anisms than amplification regarding EGFR gene 
(Ekstrand et al. 1992). Short deletions and point muta-
tions have been already identiﬁ  ed in NSCLC patients 
(Janne et al. 2006). Exons 18–21 that encode the intra-
cellular ATP-binding domain (tyrosine-kinase chains) 
represent “hot spots” of somatic mutations, including 
deletions in exon 19, small in-frame insertions in exon 
20 and mis-sense mutations in exons 18–20 (Yang et 
al. 2006). Large deletions of the extracellular domain 
of the receptor are rare-genetic events in NSCLC 
comparing to other neoplasms, such as glioblastomas 
(Moscatello et al. 1995; Frederick et al. 2002). Another 
mechanism of EGFR overactivation is the establish-
ment of an autocrine feedback loop. Self-production 
of EGF or TGF-α ligands leads to receptor activation 
and ﬁ  nally enhanced signaling. A study showed that 
among EGFR-positive primary lung ACs, overall 
survival was signiﬁ  cantly poorer for patients demon-
strating high protein levels of those ligands than the 
others, which characterized by low or negative expres-
sion (Tateishi et al. 1990). Almost recently, another 
study analyzing EGFR gene status by FISH and PCR 
methods identiﬁ  ed a subset of patients who were 
characterized by simultaneous gene ampliﬁ  cation and 
point mutations (Argiris et al. 2006).
Prognostic implication of EGFR protein expres-
sion levels, somatic mutations or/and gene copy 
number remains under investigation. Some studies 
have shown controversial results with regard to the 
response rate in agents, such as monoclonal anti-
bodies or intracellular inhibitors. Among them 
statistical signiﬁ  cance has been achieved associ-
ating EGFR expression and/or point mutations to 
monotherapy or combined therapy strategies 
including geﬁ  tinib, erlotibin and conventional 
chemotherapeutic drugs (Giaccone et al. 2004; Pao 
et al. 2006; Han et al. 2006). In contrast, application 
of monoclonal antibody targeted therapies is under 
investigation. Phase II–III studies using cetuximab, 
a monoclonal human-murine chimeric antibody 
against the extracellular domain of the receptor, 
showed that a small subset of patients might earn 
survival beneﬁ  ts (Baselga et al. 2000; Rosell et al. 
2004). Using colon cancer tissues as a substrate 
for combined IHC and molecular analysis (FISH 
and PCR), a recently published study showed that 
EGFR copy number and non-protein overexpres-
sion is linked with prognosis and patients demon-
strated this speciﬁ  c gene deregulation mechanism 
probably earn survival beneﬁ  ts, responding to 
monoclonal antibody treatment (Moroni et al. 
2005). In our study, we used a monoclonal antibody 
targeting predominantly the extracellular domain 
of the receptor for IHC analysis, because cetux-
imab binds to this site.
In the current study, also, VEGF protein expression 
levels were associated to stage of the examined tumors 
and to smoking status. Cigarette smoke is responsible 
for the multiple genetic abnormalities observed in lung 
cancer, even before morphologic changes are identi-
ﬁ  ed in the normal appearing bronchial mucosa by 
conventional light microscopy (Sekido et al. 2003). In 
our study, we found a statistical signiﬁ  cance corre-
lating smoking history and chromosome 7 instability, 
reﬂ  ecting probably this genetic imbalance. Interest-
ingly, a high concordance was assessed analyzing 
EGFR and VEGF co-expression. Both of those 
proteins are involved in the angiogenetic process and 
for this reason cetuximab and bevacizumab—a 282
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recombinant humanized anti-VEGF monoclonal 
antibody—share similar activity (Ciardiello et al. 
2000). A number of studies have proven a clear corre-
lation between VEGF expression, microvessel density, 
and impaired prognosis. In addition, encouraging 
results regarding survival status were observed by the 
application of combined targeted (monoclonal anti-
bodies) and conventional therapeutic regiments 
(Lyseng-Williamson et al. 2006; Gridelli et al. 2006).  
Furthermore, imbalances between receptors and their 
ligands, such as VEGFR-3 and VEGF-C are poten-
tially involved in the progression of NSCLC promoting 
lymph node metastasis (Takizawa et al. 2006). 
For quite a long time, IHC has been the method 
of protein expression evaluation in pathologic 
samples. Despite its relatively low cost and 
straightforward concept, immunostaining results 
can be divergent mainly due to varying sensitivity 
and speciﬁ  city of commercially available anti-
bodies, differences in tissue processing, lack of 
universal standard and inter observer differences 
in evaluating the staining results due to subjective-
ness (Park et al. 2003). In the present study, 
co-evaluation of the EGFR gene status with EGFR 
protein overexpression provides greater insight and 
meaningful information than EGFR protein 
overexpression alone. Detection of molecular 
alterations, such as aneuploidy or gene deletion/
ampliﬁ  cation, improves the level of discrimination 
between sub-groups of patients and provides 
valuable molecular information for application of 
targeted therapies. Recently, CISH has drawn more 
attention, since it is capable of evaluating gene 
ampliﬁ  cation/deletion, chromosome aneuploidy or 
chromosomal translocations simultaneously with 
tissue morphology on the same slide, using routine 
light microscopy under low magniﬁ  cation. Several 
studies have shown that CISH is an alternative to 
ﬂ  uoresence in situ hybridization (FISH) method 
and both of them demonstrate a high level of 
concordance, comparing their results (92–98%) in 
the cases of HER2/neu gene status assessment 
(Park et al. 2003). It has been used to detect 
accurately and practically EGFR gene and Chr 7 
status in pancreatic ductal adenocarcinomas or in 
glioblastomas and almost recently in NSCLCs 
(Tsiambas et al. 2006a,b; Koynova, 2005).
CIA methods can be applied to both Cytology 
and Histology (Gil 2002). Comparing the results 
obtained by the performance of conventional esti-
mation (2+, 3+) to those of quantitative analysis 
(staining intensity values), we observed that 
although there is a strong concordance (100%) in 
the overexpression group, computerized image 
analysis is a more accurate method than the 
conventional eye microscopy for the evaluation of 
borderline protein expression levels. During digital 
analysis procedure cases characterized as borderline 
by conventional eye microscopy evaluation, 
(2+ or 3+) were found to be distinct (different 
numerical values). Cases characterized as High 
level staining intensity demonstrated values 
ranging between 67 and 112. Therefore, there was 
a ”window” of values (6 gray scale levels) 
comparing them to Moderate level of staining 
intensity (values 118), which was impossible to 
be calculated by conventional interpretation 
performed by the responsible pathologist. This 
observation is easily explained because the human 
eye can distinguish less than 200 gray levels of 
staining intensity. In contrast, commercial available 
image analysis software based on 8-bit or higher 
processors discriminate at least 256 continuous 
intensity values providing accurate results for the 
interpretation of immunohistochemical staining, 
according to our previous published experience 
(Tsiambas et al. 2006c).
In conclusion, we support the idea that EGFR 
and VEGF molecules play an important role in the 
progression and biological behavior of NSCLC 
(correlation to stage of the tumors). Identiﬁ  cation 
of patients who are eligible for combined anti-
EGFR/VEGF targeted therapeutic strategies has 
been based on EGFR gene deregulation mechanism 
(ampliﬁ  cation or mutations) combined to VEGF 
overexpression. 
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